Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.55 |
| ▸ | PTAFR | P25105 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186612 | 1.00 | FAAH (0.67) | FAAHMAPTLMNAPOLBEPHX2 | |
| SCHEMBL8422210 | 0.86 | HPGD (0.63) | FAAHMAPTTDP1L3MBTL1CYP3A4 | |
| SCHEMBL11085067 | 0.86 | MAPT (0.86) | FAAHMAPTLMNAPOLBEPHX2 | |
| SCHEMBL7761440 | 0.86 | MAPT (0.86) | FAAHMAPTLMNAPOLBEPHX2 | |
| SCHEMBL18381301 | 0.86 | MAPT (0.59) | FAAHMAPTLMNACYP3A4MEN1 | |
| SCHEMBL16610103 | 0.86 | CYP3A4 (0.61) | MAPTLMNACYP3A4MEN1KMT2A | |
| SCHEMBL25407680 | 0.85 | FAAH (0.51) | FAAHMAPTLMNAPOLBEPHX2 | |
| SCHEMBL25407687 | 0.85 | FAAH (0.51) | FAAHMAPTLMNAPOLBEPHX2 | |
| SCHEMBL18381201 | 0.84 | CYP3A4 (0.67) | MAPTLMNACYP3A4MEN1KMT2A | |
| SCHEMBL16353740 | 0.84 | TBXAS1 (0.67) | MAPTLMNACYP3A4TBXAS1PTAFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | FAAH 235/4885MAPT 735/4885LMNA 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.